Yahoo Finance

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Seeking Alpha

Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
Business Insider

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and ...
Yahoo Finance

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Seeking Alpha

Recursion: AI Is Only As Good As The Data

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...
The Motley Fool

Recursion's path to doubling

Recursion Pharmaceuticals' market cap currently stands at just over $2 billion. The math is simple: To double, the company will need its market cap to increase to more than $4 billion. The best way to ...
GEN

As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials

With at least seven of its programs expected to begin human trials or read out clinical data during 2025, artificial intelligence (AI)-based drug developer Recursion Pharmaceuticals says it has begun ...
RTTNews

Recursion To Receive $10 Mln Milestone Payment As Sanofi Selects Immunology Drug Candidate

Recursion Pharmaceuticals Inc. announced Thursday that Sanofi has selected the first development candidate under their research collaboration, triggering a $10 million milestone p ...
Nasdaq

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio SALT LAKE CITY, Nov. 09, 2023 ...
GEN

Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine

Under the combination, first announced in August, Exscientia will become a wholly-owned subsidiary of Recursion, creating a trans-Atlantic AI powerhouse with a pipeline of more than 10 clinical and ...
The Globe and Mail

Recursion updates Q2 results and AI-driven pipeline

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities ...
MarketScreener

Recursion Pharmaceuticals, Inc. Announces Sanofi Options Potential First-In-Class Immunology Development Candidate From Their Collaboration

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...